Shots: mAbxience will equip their state-of-the-art cGMP facility in Spain with an ABEC 4,000L CSR Bioreactor The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity […]readmore
Tags : Collaborates
Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration […]readmore
Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration Takeda gets an […]readmore
Shots: The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented, de-identified clinical and genomic data to support Merck’s […]readmore
Shots: Amathus to receive upfront and will be eligible for ~$500M milestones/program, if Merck exercise its option and will be responsible for identifying & progressing novel chaperone activators through preclinical […]readmore
Shots: NCCN collaborates with Pfizer to select ten projects to receive funding and strengthen innovations to improve the lives of people with cancer and adopt biosimilars in oncology NCCN committed […]readmore
Shots: The companies will co-develop & co-commercialize the combination of Gilead’s Lenacapavir and Merck’s Islatravir in long-acting oral & injectable formulations for HIV. Gilead & Merck will share global development […]readmore
Shots: Cardinal Health signed an agreement to divest its Cordis medical device business to H&F for ~ $1B including liabilities and working capital accounts. The transaction is expected to close […]readmore
Shots: SMA Foundation and PTC will provide an initial investment of up to $60M in research to discover & develop regenerative treatments in neuromuscular diseases The focus of the agreement […]readmore
Shots: Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future Additionally, Biolojic is eligible to receive royalties […]readmore